MARKET

LMAT

LMAT

Lemaitre Vasculr
NASDAQ

Real-time Quotes | Nasdaq Last Sale

43.68
-0.65
-1.47%
Opening 11:47 05/24 EDT
OPEN
44.03
PREV CLOSE
44.33
HIGH
44.36
LOW
43.21
VOLUME
18.97K
TURNOVER
601.64K
52 WEEK HIGH
64.50
52 WEEK LOW
38.21
MARKET CAP
958.86M
P/E (TTM)
35.10
1D
5D
1M
3M
1Y
5Y
LeMaitre to Present at Upcoming Investor Conferences
BURLINGTON, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it is participating in two upcoming investor conferences. JJ Pellegrino, Chief Financial Officer, will present at the UBS Global Healthcare Confe...
GlobeNewswire · 05/16 20:58
Should You Buy LeMaitre Vascular, Inc. (NASDAQ:LMAT) For Its Upcoming Dividend?
It looks like LeMaitre Vascular, Inc. ( NASDAQ:LMAT ) is about to go ex-dividend in the next two days. The ex-dividend...
Simply Wall St. · 05/13 12:24
LeMaitre Vascular declares $0.125 dividend
LeMaitre Vascular (NASDAQ:LMAT) declares $0.125/share quarterly dividend, in line with previous. Forward yield 1.14% Payable June 2; for shareholders of record May 17; ex-div May 16. See LMAT Dividend Scorecard,
Seekingalpha · 04/29 19:10
LeMaitre dips 4% on guiding Q2 and FY22 below EPS and revenue
LeMaitre (LMAT) -4% on reporting Q2 EPS of $0.27 missing consensus by 1 cent. Sales of $39.6M, +10% was driven by Artegraft, XenoSure, carotid shunts, allografts and valvulotomes. By geography, sales were
Seekingalpha · 04/29 18:02
LeMaitre Vascular's Q1 Earnings Slip, Sales Rise; Lowers 2022 Guidance, Issues Q2 Outlook
MT Newswires · 04/29 11:37
--Barrington Lowers LeMaitre Vascular's Price Target to $50 From $54, Maintains Outperform Rating
MT Newswires · 04/29 11:15
LeMaitre Vascular (LMAT) Q1 Earnings Miss Estimates
LeMaitre (LMAT) delivered earnings and revenue surprises of -3.57% and 1.84%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 04/28 21:55
LeMaitre Vascular Q1 EPS $0.27 Misses $0.28 Estimate, Sales $39.60M Beat $38.75M Estimate
LeMaitre Vascular (NASDAQ:LMAT) reported quarterly earnings of $0.27 per share which missed the analyst consensus estimate of $0.28 by 3.57 percent. This is a 3.57 percent decrease over earnings of $0.28 per share from
Benzinga · 04/28 20:40
More
No Data
Learn about the latest financial forecast of LMAT. Analyze the recent business situations of Lemaitre Vasculr through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

37.50%Strong Buy
25.00%Buy
37.50%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average LMAT stock price target is 59.86 with a high estimate of 76.00 and a low estimate of 45.00.
High76.00
Average59.86
Low45.00
Current 43.68
EPS
Actual
Estimate
0.100.200.300.40
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 242
Institutional Holdings: 21.19M
% Owned: 96.51%
Shares Outstanding: 21.95M
TypeInstitutionsShares
Increased
60
797.81K
New
28
117.44K
Decreased
58
396.31K
Sold Out
28
165.09K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
-1.11%
Healthcare Equipment & Supplies
-1.36%
Key Executives
Chairman/Chief Executive Officer/Director
George LeMaitre
President/Director
David Roberts
Chief Financial Officer/Director
Joseph Pellegrino
Senior Vice President/General Counsel
Laurie Churchill
Senior Vice President
Andrew Hodgkinson
Senior Vice President
Trent Kamke
Senior Vice President
Stephane Maier
Vice President/Director of Sales
Giovannella Deiure
Vice President/Director of Sales
Chance Kriesel
Vice President/Director of Marketing
Kimberly Cieslak
Vice President
Roli Kumar-Choudhury
Vice President
Jonathan Ngau
Vice President
Jacob Petersen
Vice President
James Russell
Vice President
Xiang Zhang
Vice President - Research & Development
Ryan Connelly
Senior Director
Kathryn Tebbe
Director of Sales
Helen Goulding
Director of Sales
Ina Leininger
Director of Human Resources
Daniel Mumford
Other
Christopher Minnett
Independent Director
Lawrence Jasinski
Independent Director
John O'Connor
Independent Director
Bridget Ross
Independent Director
John Roush
No Data
No Data
About LMAT
LeMaitre Vascular, Inc. is a medical device company. The Company provides medical devices and human tissue cryopreservation services used in the treatment of peripheral vascular disease, end-stage renal disease and cardiovascular disease. It develops, manufactures and markets vascular devices to address the needs of vascular surgeons and other specialties, such as cardiac surgeons, general surgeons and neurosurgeons. Its portfolio of devices consists of products that are used in arteries and veins outside of the heart, which includes the LeMaitre valvulotome, the XenoSure biologic patch, the Artegraft collagen vascular graft, the Pruitt F3 carotid shunt, VascuTape radiopaque tape and Syntel embolectomy catheters. Its product line includes Valvulotomes, Surgical Glue, Remote Endarterectomy Devices, Radiopaque Tape, Powered Phlebectomy, ePTFE Vascular Grafts, Polyester Vascular Grafts, Ovine Vascular Grafts, Closure Systems, Carotid Shunts, Allografts, Angioscopes and many others.

Webull offers kinds of LeMaitre Vascular Inc stock information, including NASDAQ:LMAT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LMAT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LMAT stock methods without spending real money on the virtual paper trading platform.